How to buy Inovio Pharmaceuticals stock | $7.94

Inovio Pharmaceuticals, Inc is a biotechnology business based in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Inovio Pharmaceuticals employs 262 staff and has a trailing 12-month revenue of around 0.00.

Inovio Pharmaceuticals stock price (NASDAQ: INO)

Use our graph to track the performance of INO stocks over time.

Inovio Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$7.94
52-week range	$5.81 - $23.05
50-day moving average	$8.69
200-day moving average	$9.36
Wall St. target price	$13.22
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.22

Buy Inovio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Inovio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Inovio Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inovio Pharmaceuticals price performance over time

Historical closes compared with the close of $7.94 from 2021-06-04

1 week (2021-07-18)	N/A
1 month (2021-06-29)	-16.07%
3 months (2021-04-29)	15.24%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Inovio Pharmaceuticals financials

Revenue TTM	$6.5 million
Gross profit TTM	$-86,834,216
Return on assets TTM	-19.04%
Return on equity TTM	-49.06%
Profit margin	0%
Book value	$2.78
Market capitalisation	$1.8 billion

TTM: trailing 12 months

Shorting Inovio Pharmaceuticals shares

There are currently 44.6 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 4.6% down from 46.7 million last month.

There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.

Inovio Pharmaceuticals's "short interest ratio" (SIR)

Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 5.9 million). Inovio Pharmaceuticals's SIR currently stands at 7.61. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 7610 shares are currently held short.

However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2164% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 216 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.

Find out more about how you can short Inovio Pharmaceuticals stock.

Inovio Pharmaceuticals share dividends

We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.

Have Inovio Pharmaceuticals's shares ever split?

Inovio Pharmaceuticals's shares were split on a 1:4 basis on 5 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.

Inovio Pharmaceuticals share price volatility

Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as $5.81 up to $23.05. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 0.6507. This would suggest that Inovio Pharmaceuticals's shares are less volatile than average (for this exchange).

Inovio Pharmaceuticals overview

Inovio Pharmaceuticals, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp. , AstraZeneca, Beijing Advaccine Biotechnology Co. , Ltd.

Frequently asked questions

What percentage of Inovio Pharmaceuticals is owned by insiders or institutions?
Currently 1.663% of Inovio Pharmaceuticals shares are held by insiders and 36.523% by institutions. How many people work for Inovio Pharmaceuticals?
Latest data suggests 262 work at Inovio Pharmaceuticals. When does the fiscal year end for Inovio Pharmaceuticals?
Inovio Pharmaceuticals's fiscal year ends in December. Where is Inovio Pharmaceuticals based?
Inovio Pharmaceuticals's address is: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 What is Inovio Pharmaceuticals's ISIN number?
Inovio Pharmaceuticals's international securities identification number is: US45773H2013 What is Inovio Pharmaceuticals's CUSIP number?
Inovio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 371916107